Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Richard

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
International Journal of Chronic Obstructive Pulmonary Disease|March 26, 2016
A cross-sectional study to assess inhalation device handling and patient satisfaction in COPDMarc Miravitlles, Jéssica Montero-Caballero, Frank Richard, et al.
Cardiology and Therapy|July 9, 2020
Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) RegistryUwe Zeymer, Christiane Lober, Andreas Wolf, et al.
Orphanet Journal of Rare Diseases|November 26, 2025
Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a studyAntonis Kattamis, Ali Taher, Vip Viprakasit, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|April 7, 2009
Chicken dapper genes are versatile markers for mesodermal tissues, embryonic muscle stem cells, neural crest cells, and neurogenic placodesLúcia Elvira Alvares, Farrah Leigh Winterbottom, Erika Cristina Jorge, et al.
Expert Review of Hematology|July 29, 2021
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical developmentJohn Porter, Ali Taher, Vip Viprakasit, et al.
Chest|October 19, 2013
Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group studyJinping Zheng, Jinghua Yang, Xiangdong Zhou, et al.
Clinical Pharmacology in Drug Development|November 20, 2018
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 TrialHans-Dirk Düngen, Lars Kober, Savina Nodari, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
International Journal of Chronic Obstructive Pulmonary Disease|March 26, 2016
A cross-sectional study to assess inhalation device handling and patient satisfaction in COPDMarc Miravitlles, Jéssica Montero-Caballero, Frank Richard, et al.
Cardiology and Therapy|July 9, 2020
Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) RegistryUwe Zeymer, Christiane Lober, Andreas Wolf, et al.
Orphanet Journal of Rare Diseases|November 26, 2025
Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a studyAntonis Kattamis, Ali Taher, Vip Viprakasit, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|April 7, 2009
Chicken dapper genes are versatile markers for mesodermal tissues, embryonic muscle stem cells, neural crest cells, and neurogenic placodesLúcia Elvira Alvares, Farrah Leigh Winterbottom, Erika Cristina Jorge, et al.
Expert Review of Hematology|July 29, 2021
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical developmentJohn Porter, Ali Taher, Vip Viprakasit, et al.
Chest|October 19, 2013
Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group studyJinping Zheng, Jinghua Yang, Xiangdong Zhou, et al.
Clinical Pharmacology in Drug Development|November 20, 2018
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 TrialHans-Dirk Düngen, Lars Kober, Savina Nodari, et al.
Pageof 2